Stability of frozen 1% voriconazole eye-drops in both glass and innovative containers.


Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
01 Jan 2020
Historique:
received: 19 07 2019
revised: 04 10 2019
accepted: 07 10 2019
pubmed: 28 10 2019
medline: 17 4 2020
entrez: 27 10 2019
Statut: ppublish

Résumé

To assess the physico-chemical stability of Voriconazole Eye-Drops (VED), when stored frozen and refrigerated once thawed, in 3 containers: Amber glass with a Low-Density PolyEthylene (LDPE) eyedropper, and two types of LDPE bottles: one classical and one with an innovative insert that maintains sterility after opening (Novelia® from Nemera). Three batches of 1% VED (10 mL) were aseptically compounded from marketed injectable voriconazole (Vfend®) diluted in sterile water for injection. VEDs were stored for three months at -20 °C in amber glass (n = 32), classical LDPE (n = 32) or innovative LDPE (n = 31) bottles. Stability-indicating (HPLC-UV-DAD) and chiral chromatography methods were developed. The stability study was conducted according to GERPAC-SFPC guidelines. At each study time, the following parameters were controlled: visual aspect, voriconazole concentration, pH and osmolality. In addition, non-visible particle count, sterility and absence of racemisation (impurity D - (2S,3R)-voriconazole) were assessed at the beginning and end of the study. Results are expressed as mean ± standard deviation. Statistical analyses were performed using non-parametric tests (α < 5%) to compare containers. When stored frozen, concentration was between 95.2 ± 1.4% and 103.6 ± 1.3% of the initial concentration (C0) with no difference between the three containers (p = 0.564; non-significant). Fifteen days after thawing, concentration was between 97.1 ± 1.6% and 98.6 ± 0.8% of C0 with no difference between containers (p = 0.278 and 0.368 for VED thawed at room temperature and at 2-8 °C, respectively). pH remained stable between each time. Osmolality was slightly higher in glass (533.17 ± 8.93 mOsm/Kg) than in plastic containers (522.17±3.31mOsm/Kg, classical LDPE; 517.5 ± 12.42 mOsm/Kg, innovative LDPE) (p = 0.022). Sterility was preserved. Degradation product areas increased slightly but remained below the limit of quantification. Impurity D was never detected. We have demonstrated that the ability of the innovative container Novelia® to maintain VED physicochemical and microbiological stability does not differ from that of amber glass and classical LDPE containers. Real life studies are required to find out if there is a potential difference between Novelia® and other containers in terms of sterility preservation.

Identifiants

pubmed: 31655210
pii: S0928-0987(19)30375-6
doi: 10.1016/j.ejps.2019.105102
pii:
doi:

Substances chimiques

Antifungal Agents 0
Ophthalmic Solutions 0
Polyethylene 9002-88-4
Voriconazole JFU09I87TR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105102

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Marine Roche (M)

CHU Lille, Institut de Pharmacie, F-59000 Lille, France; Univ. Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.

Damien Lannoy (D)

CHU Lille, Institut de Pharmacie, F-59000 Lille, France; Univ. Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.

Florence Bourdon (F)

CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

Cécile Danel (C)

Univ. Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.

Pierre Labalette (P)

CHU Lille, Service d'ophtalmologie, F-59000 Lille, France.

Christophe Berneron (C)

CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

Nicolas Simon (N)

CHU Lille, Institut de Pharmacie, F-59000 Lille, France; Univ. Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.

Pascal Odou (P)

CHU Lille, Institut de Pharmacie, F-59000 Lille, France; Univ. Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.

Articles similaires

Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol
Humans Retrospective Studies Male Female Child
Leishmania donovani Animals Antifungal Agents Mice Azoles
1.00
Humans Paper Contraceptives, Oral Carbon Dioxide Female

Classifications MeSH